Should Raised Earnings Outlook Require Action From Novartis (SWX:NOVN) Investors?

• Novartis reported Q3 2026 sales of US$14.52b and net income of US$1.20b, and then raised its full year core operating income outlook after margin expansion and strong contributions from priority medicines.

• The earnings report landed alongside positive late stage data for remibrutinib in relapsing multiple sclerosis and six year survival results for Kisqali in early breast cancer. This combination reinforced how pipeline assets connect directly to Novartis' current profit story.

• We will now look at how Novartis' updated earnings outlook, supported by remibrutinib progress, may reshape its broader investment narrative.

Compare how Novartis' late stage drug wins stack up against other pharma opportunities by screening for 223 resilient stocks with low risk scores that are aligned with resilient pipelines and stronger balance sheet profiles.

Novartis Investment Narrative Recap

To own Novartis, you need to believe the current mix of priority brands and late stage drugs can keep offsetting patent, pricing and competition headwinds. Q3 2026 showed US$14.52b in sales with net income of US$1.20b, alongside higher core operating income guidance after margin expansion. This keeps execution in focus rather than rewiring the story.

In the short term, the key catalyst is delivery against that upgraded profit outlook while integrating new launches such as Rhapsido and expanded Pluvicto indications. The biggest risk remains earnings pressure from generic erosion and pricing reform, especially with net income for the quarter and year to date below the prior period, despite revenue progress.

Among the recent updates, the remibrutinib Phase III data in relapsing multiple sclerosis looks most tied to the current earnings story. The oral BTK inhibitor achieved superior relapse control versus teriflunomide and showed a clean liver safety profile in these trials, and Novartis now plans global regulatory filings based on those results.

For shareholders, that matters because remibrutinib sits alongside Kisqali, Cosentyx, Kesimpta and Pluvicto as part of the next wave that management is counting on to support margins and cash flow. Execution risk remains high in late stage development and pricing, so monitoring regulatory decisions, label details and early uptake will be critical for judging whether the upgraded income outlook is well supported.

Novartis' narrative projects US$67.6b revenue and US$18.7b earnings by 2029. This assumes 6.0% yearly revenue growth and an earnings increase of about US$5.9b from US$12.8b today.